Melbourne, Australia, November 30, 2016:  Australian medtech startup 4Dx is making a bold foray into the US diagnostics marketplace, inking deals with major US hospitals and attracting one of the country’s most prominent oncologists to join its Board of Directors.

Dr Bob Figlin will join the 4Dx board from December 1st.  Dr Figlin is Deputy Director of the Integrated Oncology Service Line, and Deputy Director at the Samuel Oschin Comprehensive Cancer Institute, part of the world-renowned Cedars-Sinai Medical Center in Los Angeles. He is also currently the director of the Hematology Oncology Division at the institute.

Dr Figlin says, “4Dx has developed some of the most promising and exciting technology I’ve ever seen in the fight against disease. It will be a privilege to be able to use my medical and business experience to assist the company through this phase of its growth.”   Dr Figlin co-founded biotechnology company Agensys, which later sold as part of a nine-figure deal.

4Dx has also established formal clinical partnerships with several of the biggest and most advanced hospitals in the US, including Cedars-Sinai, The Cleveland Clinic, the Children’s Hospital Los Angeles, Virginia Commonwealth University, and the University of North Carolina at Chapel Hill.

The unique software developed by 4Dx generates moving, ultra-high-resolution images of motion and airflow in lung tissue. This revolutionary technology enables clinicians to view and measure abnormal lung function at the earliest stages of disease providing clinicians with new technology to significantly enhance traditional respiratory diagnostic methods.

The company is currently accepting investment monies which will be used to finance a US expansion and further clinical trials as it moves towards FDA approval, which is anticipated for next year.  The Series A Capital Round is expected to close oversubscribed on December 9th.  A second round of fundraising is planned for early 2017.